Immunotherapy in glioblastoma treatment: Current state and future prospects

SLR Pinheiro, FFB Lemos, HS Marques… - World Journal of …, 2023 - pmc.ncbi.nlm.nih.gov
Glioblastoma remains as the most common and aggressive malignant brain tumor, standing
with a poor prognosis and treatment prospective. Despite the aggressive standard care …

Glioblastoma vaccines: past, present, and opportunities

Z ** by engineered extracellular vesicles for targeted glioblastoma therapy
R Liang, H Lu, H Zhu, G Liang, J Zhang, J Gao… - Journal of Controlled …, 2024 - Elsevier
The poor outcome of glioblastoma multiforme (GBM) treated with immunotherapy is
attributed to the profound immunosuppressive tumor microenvironment (TME) and the lack …

Enhancement of Microglia Functions by Developed Nano‐Immuno‐Synergist to Ameliorate Immunodeficiency for Malignant Glioma Treatment

M Xu, Y Cheng, R Meng, P Yang… - Advanced …, 2023 - Wiley Online Library
Resident microglia are key factors in mediating immunity against brain tumors, but the
microglia in malignant glioma are functionally impaired. Little immunotherapy is explored to …

Dual role of CXCL8 in maintaining the mesenchymal state of glioblastoma stem cells and M2-like tumor-associated macrophages

W Yuan, Q Zhang, D Gu, C Lu, D Dixit… - Clinical Cancer …, 2023 - aacrjournals.org
Purpose: The dynamic interplay between glioblastoma stem cells (GSC) and tumor-
associated macrophages (TAM) sculpts the tumor immune microenvironment (TIME) and …

Downregulated ferroptosis‐related gene SQLE facilitates temozolomide chemoresistance, and invasion and affects immune regulation in glioblastoma

L Yao, J Li, X Zhang, L Zhou… - CNS Neuroscience & …, 2022 - Wiley Online Library
Chemoresistance in patients with glioblastoma multiforme (GBM) is a common reason
hindering the success of treatment. Recently, ferroptosis has been reported to be associated …